Compare Abbott Laboratories (ABT) vs McDonald's Corp (MCD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs McDonald's Corp — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while McDonald's Corp trades at $277.36 (market cap $200.51B). The key difference: McDonald's Corp is the larger of the two by market cap, and McDonald's Corp pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| ABT | MCD | |
|---|---|---|
Market Cap | $166.94B | $200.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $341.06 |
52-Week Low | $82.57 | $264.54 |
Enterprise Value | $193.69B | $254.22B |
Dividend Yield | 2.63% | 2.64% |
Volume | — | 2,230,036 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
McDonald's (MCD) trades at $279.5, down 0.4% on the day, as the stock navigates a challenging consumer environment. The company reported solid Q1 2026 earnings that beat expectations, with revenue reaching $26.89B in 2025 and a robust net income margin of 31.62%. Technical analysis shows a bullish overall signal despite mixed moving averages, with key support at $275 and resistance at $282. Recent news highlights the company's new 'McDonald's>NEXT' growth strategy focused on automation and menu innovation to win back customers.
The outlook for MCD is cautiously optimistic, supported by strong analyst consensus (58% Buy rating) and a $325.50 price target implying significant upside. Investment opportunities include the company's durable franchise model, consistent dividend payments, and strategic initiatives to improve operations. Key risks involve persistent inflationary pressures on franchisee margins, intense competition in the value segment, and execution challenges of the new growth strategy amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
